Tumor-tropic myeloma and B-cells

The term "Tumor-tropic myeloma and B-cells" does not refer to a specific molecular target, receptor, or enzyme, but rather describes a biological property and the cell types associated with it [1, 5]. Tumor tropism is the characteristic ability of certain cells, such as malignant plasma cells in multiple myeloma and specific B-cell subsets, to migrate toward and home into tumor microenvironments or the bone marrow niche [7, 9]. This migratory behavior is primarily driven by the interaction between chemokine receptors on the cell surface, most notably CXCR4, and chemoattractant gradients like CXCL12 (SDF-1) produced by the tumor stroma [1, 9]. While these cells are the focus of numerous therapeutic interventions, the actual molecular targets for drug development are specific surface proteins like B-cell maturation antigen (BCMA), CD38, or CD19, or the signaling pathways that mediate their tropism [8, 9]. Because the provided name identifies a cell population and its migratory characteristics rather than a distinct protein or molecule, it is classified as an incorrect or non-canonical target name for drug development purposes [4, 9].

Other names

Tumor-homing B-cellsTumor-tropic myeloma cellsBone marrow-tropic myeloma cells

Not applicable as this term describes a cell population and its migratory behavior rather than a specific molecular target.